实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (6): 811-814.doi: 10.3969/j.issn.1672-5069.2023.06.011

• 非酒精性脂肪性肝病 • 上一篇    下一篇

18F-FDG摄取量诊断非酒精性脂肪性肝病患者罹患冠状动脉粥样硬化性心脏病探讨*

邵孝如, 周筱, 葛颖颖   

  1. 210000 南京市 南京医科大学第四附属医院放射科(邵孝如);南京大学医学院附属南京鼓楼医院放射科(周筱);南京明基医院放射科(葛颖颖)
  • 收稿日期:2022-12-16 出版日期:2023-11-10 发布日期:2023-11-20
  • 作者简介:邵孝如,女,36岁,大学本科,主管技师。研究方向:放射影像学诊断。E-mail:shao138515guyan@163.com
  • 基金资助:
    * 江苏省自然科学基金资助项目(编号:BK20201131)

Diagnosis of coronary atherosclerotic heart disease in patients with nonalcoholic fatty liver disease by CCTA and18F-FDG intake

Shao Xiaoru, Zhou Xiao, Ge Yingying   

  1. Department of Radiology, Fourth Affiliated Hospital, Nanjing Medical University, Nanjing 210000,Jiangsu Province, China
  • Received:2022-12-16 Online:2023-11-10 Published:2023-11-20

摘要: 目的 探讨应用18F-FDG摄取量诊断非酒精性脂肪性肝病(NAFLD)患者罹患冠状动脉粥样硬化性心脏病(CHD)的可行性。方法 2020年1月~2021年12月我院诊治的NAFLD患者120例,均接受冠状动脉CT血管成像(CCTA)和18F-氟代脱氧葡萄糖(FDG)正电子发射计算机断层显像(PET/CT)检查,绘制感兴趣区域(ROI),测量心脏标准摄取值【记录各层最大值(SUVmyo)】和肝脏SUV(SUVliv),计算SUVmyo/SUVliv比值(SUVratio)。结果 在120例NAFLD患者中,经CCTA检查发现CHD患者28例;CHD组体质指数、空腹血糖、总胆固醇和甘油三酯水平分别为(28.6±2.2)kg/m2、(6.9±2.1)mmol/L、(6.3±0.9)mmol/L和(3.7±0.4)mmol/L,均显著高于NAFLD组【分别为(25.1±2.3)kg/m2、(5.2±1.5)mmol/L、(4.4±0.5)mmol/L和(1.6±0.2)mmol/L,P<0.05】,合并代谢综合征、高血压和糖尿病占比分别为28.6%、32.1%和28.6%,均显著高于NAFLD组的2.1%、10.8%和4.3%(P<0.05);CCTA检查发现,CHD组非钙化性斑块和非钙化斑块明显狭窄占比分别为28.6%和25.0%,均显著高于NAFLD组的4.3%和2.2%(P<0.05);18F-FDG PET/CT检查显示,CHD组SUVmyo和SUVratio分别为(3.8±1.1)和(1.6±0.3),均显著低于NAFLD组【分别为(6.8±1.6)和(3.1±0.9),P<0.05】。结论 采用CCTA和PET/CT检查可以帮助筛查NAFLD患者CHD,其准确性还需与冠状动脉造影比较。

关键词: 非酒精性脂肪性肝病, 冠状动脉粥样硬化性心脏病, 冠状动脉CT血管成像, 18F-FDG摄取量, 诊断

Abstract: Objective The aim of this study was to investigate the diagnosis of coronary atherosclerotic heart disease (CHD) in patients with nonalcoholic fatty liver disease (NAFLD) by coronary artery CT angiography (CCTA) and 18F-FDG positron emission computed tomography (PET/CT). Methods 120 patients with NAFLD were recruited in our hospital between January 2020 and December 2021, and all underwent CCTA and PET/CT scan. The myocardial and liver standard uptake values (SUV) were obtained and recorded as SUVmyo, SUVliv and SUVmyo/SUVliv ratio(SUVratio). Results Out of the 120 patients with NAFLD, the CCTA found CHD in 28 cases (23.3%); the body mass index, fasting blood glucose, total cholesterol and triglyceride levels in patients with NAFLD and CHD were(28.6±2.2)kg/m2,(6.9±2.1)mmol/L, (6.3±0.9)mmol/L and (3.7±0.4)mmol/L, all significantly higher than[(25.1±2.3)kg/m2, (5.2±1.5)mmol/L, (4.4±0.5)mmol/L and (1.6±0.2)mmol/L, P<0.05], and the concomitant proportions of metabolic syndrome, hypertension and diabetes were 28.6%, 32.1% and 28.6%, all much higher than 2.1%, 10.8% and 4.3%(P<0.05) in patients with NAFLD; the CCTA scan showed the non-calcified plaque and non-calcified plaque stenosis in coronary arteries in patients with CHD were 28.6% and 25.0%, both much higher than 4.3% and 2.2%(P<0.05) in patients with NAFLD; the 18F-FDG PET/CT scan demonstrated that the SUVmyo and the SUVratio in patients with CHD were (3.8±1.1) and (1.6±0.3), both significantly lower than[(6.8±1.6) and (3.1±0.9), respectively, P<0.05] in patients with NAFLD alone. Conclusion The screening of CHD in patients with NAFLD by CCTA and PET/CT scan is convenient and safe, which might be verified by coronary angiography.

Key words: Non-alcoholic fatty liver diseases, Coronary atherosclerotic heart disease, 18F-FDG intake, Coronary artery CT angiography, Diagnosis